Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the connection between PI3K-AKT-mTOR pathway mutations and heritable skin diseases characterized by tissue overgrowth, but it reports no new clinical results.

This case report observed that oral tofacitinib treatment resolved both alopecia universalis and plaque psoriasis in a patient, possibly by targeting shared inflammatory pathways.

This study found that in alopecia areata, treatment with the oral JAK-inhibitor tofacitinib decreased clonally expanded CD8⁺ T cells in the scalp, but many expanded clones did not completely disappear, potentially leading to relapse after stopping treatment.

This study found that low-dose methotrexate significantly reduced the steroid requirement in subjects with corticosteroid-requiring asthma without altering their clinical status or causing significant complications.

This study found that a new treatment candidate may effectively prevent and promote recovery from chemotherapy-induced alopecia by normalizing apoptosis and reducing inflammation in cancer patients.

Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.

No results are provided in this article as it lacks an available abstract, making it unclear what effects apremilast and tofacitinib have in a humanized mouse model of alopecia areata.

In this retrospective study at Hiroshima University, methotrexate effectively controlled ocular inflammation in Japanese patients with non-infectious uveitis over 6 to 24 months, but a high incidence of adverse effects indicates careful monitoring and dose adjustments are important.

In this study, two patients with refractory juvenile dermatomyositis improved clinically and in disease activity after receiving the JAK inhibitor tofacitinib, showing potential effects in managing the condition.

This study describes and characterizes four cases of alopecia areata induced by immune checkpoint inhibitor therapy in cancer patients, highlighting the importance of recognizing and managing these hair-related adverse events.

This review highlights that deucravacitinib, a selective TYK2 inhibitor, shows promise as an effective treatment for psoriasis and other inflammatory skin diseases, though real-world evidence beyond psoriasis is still emerging.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

This study suggests that the emulsion extract of brevilin A from Centipeda minima may stimulate hair regrowth in individuals with mild to moderate vertex balding by inhibiting JAK3.

This review found that oral methotrexate plus oral prednisone may improve disease activity or damage in juvenile active morphea compared to placebo plus prednisone, but adverse events may slightly increase.

In this study, a combined therapy of Cyclosporine A and ketoconazole resolved anal furunculosis in dogs within 10 weeks, but recurrences were noted in about 37% of cases.

This case study reports on an adult with metastatic Crohn's disease treated with infliximab over 4.5 years, providing valuable follow-up data in this context.

The study reported that vismodegib showed significant effectiveness in treating basal cell carcinoma, particularly in patients with Gorlin-Goltz syndrome or locally advanced BCC, but also highlighted substantial side effects, requiring careful management to prevent treatment resistance and maintain remission.

This article discusses the development of targeted prodrug conjugates aimed at selectively attacking cancer cells while avoiding healthy ones, but reports no experimental results yet.

This study found that topical corticosteroid foams are effective and generally preferred by patients for a variety of corticosteroid-responsive skin conditions, demonstrating significant clinical benefits such as improved psoriasis symptoms and hair regrowth in alopecia areata compared to traditional forms.

This case study reported that a 24-year-old patient with severe, treatment-resistant alopecia areata experienced excellent clinical improvement after one month of treatment with tofacitinib, a JAK inhibitor.

This case report highlights a potential association between etanercept, a TNF-α blocker, and the onset of alopecia areata, suggesting complex interactions between anti-TNF-α treatments and hair follicle growth.

In this study, neoadjuvant treatment with durvalumab combined with albumin-bound paclitaxel and carboplatin in patients with driver gene-negative stage III NSCLC showed a 65% objective response rate and was associated with high pathological response rates and improved immune function, with most adverse events being mild.

This study found that using ectopic expression of CD24 is a promising approach for selecting genetically modified human epidermal stem cells for safe cutaneous gene therapy in cancer-prone conditions.

This case report describes a 12-year-old male dog with hepatoid cell carcinoma, showing significant health improvement after a month of bioregulatory therapy, including gastroenteropathy resolution, hair regrowth, and restored vision.

This study found that cyclosporine A can alter lipid bilayer properties and does so at a slower rate, suggesting conformational shifts may facilitate its membrane crossing.

This study reports that mesenchymal stromal cell-derived extracellular vesicle injections led to complete hair regrowth in a patient with persistent chemotherapy-induced alopecia.

Secukinumab effectively treated a difficult case of folliculitis decalvans.

This randomized controlled trial found that intralesional injections of triamcinolone were significantly more effective than platelet rich plasma for treating alopecia areata on the scalp, although platelet rich plasma was considered a viable alternative due to its lack of serious side effects.

This review reports no new results and discusses various topical treatments, noting that fluocortin butyl ester offers anti-inflammatory effects without systemic side effects, while combinations outperform single-agent therapies in managing hyperpigmentation.

This report highlights that oral Janus kinase inhibitors, including baricitinib, ritlecitinib, deuruxolitinib, and brepocitinib, show promise for treating alopecia areata by promoting substantial hair regrowth with mild-to-moderate side effects, positioning them as a favorable alternative to corticosteroids.